Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $127.60 USD
Change Today +1.98 / 1.58%
Volume 1.0M
VRTX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Mexico
Frankfurt
As of 11:24 AM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

50 Northern Avenue

Boston, MA 02210

United States

Phone: 617-341-6100

Fax:

s and patent applications covering VX-803 and VX-970, and the use of VX-803 and VX-970 to treat oncology indications. The U.S. and foreign patents and patent applications covering VX-210 and the use of VX-210 to treat neurology indications. The U.S. and foreign patents and patent applications covering the manufacture, pharmaceutical compositions, related solid forms, formulations, dosing regimens, and methods of use of these compounds, including ivacaftor and lumacaftor. The company has a U.S. patent that covers the composition-of-matter of ivacaftor that it expects would provide intellectual property protection in the United States through its expiration date in 2027. The company has a European patent that covers the composition-of-matter of ivacaftor that it expects would provide intellectual property protection in the European Union through its expiration date in 2025, subject to potential extension. The company has a European patent that covers the composition of matter of lumacaftor that it expects would provide intellectual property protection in the European Union through its expiration date in 2026, subject to potential extension. The company has pending applications in the United States covering the composition-of-matter of lumacaftor. The company has a United States patent that covers the composition of matter of VX-661 that it expects would provide intellectual property protection in the United States through its expiration date in 2027, subject to potential extension. The company has pending applications in the European Union covering the composition-of-matter of VX-661. Government Regulation Products manufactured or distributed by the company pursuant to the FDA approvals are subject to continuing regulation by the FDA. The company is subject to regulation in the United States under the Occupational Safety and Health Act; the Environmental Protection Act; the Toxic Substances Control Act; the Resource Conservation and Recovery Act; and other federal, state, local, and foreign statutes and regulations. History Vertex Pharmaceuticals Incorporated was founded in 1989. The company was incorporated in Massachusetts in 1989.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRTX:US $127.60 USD +1.98

VRTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $66.29 USD -2.10
BioMarin Pharmaceutical Inc $141.29 USD -3.03
Incyte Corp $100.66 USD -3.08
Jazz Pharmaceuticals PLC $188.31 USD -2.37
Sigma-Aldrich Corp $139.73 USD +0.15
View Industry Companies
 

Industry Analysis

VRTX

Industry Average

Valuation VRTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 51.2x
Price/Book 32.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 48.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERTEX PHARMACEUTICALS INC, please visit www.vrtx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.